Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Deuterated Psilocybin Products

This patent broadly covers pharmaceutical compositions comprising deuterated forms of psilocybin.\n\xe2\x80\x9cPsilocybin has shown incredible promise in recent clinical studies as a potential treatment for major depressive disorder and other psychiatric diseases and disorders,\xe2\x80\x9d said Bradford C. Sippy, Founder and CEO of Lennham.